drugset / Trial / NCT07513441

A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)

NCT07513441 ↗

Phase 1 Not yet recruiting 10 enrolled H. Lundbeck A/S
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.

Timeline

Start
2026-03-31
Primary completion
2027-05-31
Completion
2027-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AF28996 Unknown — Oral

Indications